Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Purpose: To investigate circulating tumor DNA (ctDNA) RAS mutant (MT) incidence before salvage-line treatment and the clinicopathological features and molecular biological factors associated with the efficacy of anti-epithelial growth factor receptor (EGFR) monoclonal antibody (mAb) rechallenge for tissue RAS / BRAF wild type (WT) metastatic colorectal cancer (mCRC). Methods: This multi-institutional retrospective observational study included 74 patients with mCRC with tissue RAS/BRAF WT refractory to first-line chemotherapy containing anti-EGFR mAb. ctDNA RAS status was assessed using the OncoBEAM™ RAS CRC Kit. We explored the clinicopathological features associated with ctDNA RAS status and the factors related to anti-EGFR mAb rechallenge efficacy in multivariate Cox proportional hazard regression. Results: The incidence of RAS MT in ctDNA was 40.5% (30/74), which was associated with primary tumor resection ( P = 0.016), liver metastasis ( P < 0.001), and high tumor marker levels ( P < 0.001). Among the 39 patients treated with anti-EGFR mAb rechallenge, those with ctDNA RAS WT showed significantly longer progression-free survival (PFS) than those with ctDNA RAS MT (median 4.1 vs. 2.7 months, hazard ratio [HR] = 0.39, P = 0.045). Patients who responded to first-line anti-EGFR mAb showed significantly longer PFS (HR = 0.21, P = 0.0026) and overall survival (OS) (HR = 0.23, P = 0.026) than those with stable disease. Conclusions: The incidence of ctDNA RAS MT mCRC was 40.5%, which was associated with liver metastases and high tumor volumes. Anti-EGFR mAb rechallenge may be effective for patients with mCRC who responded to first-line chemotherapy containing anti-EGFR mAb. No patients with RAS MT in ctDNA responded to anti-EGFR mAb rechallenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies such as CRICKET and CAVE have demonstrated that patients with elimination of resistant RAS and EGFR mutant clones can regain sensitivity to cetuximab-based therapy, reinforcing the need to integrate molecular monitoring into clinical decision-making [68,69].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [69]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
Kanda, Y. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.244 · Cited by 18,767 · cited 1×
“Statistical analyses were performed using EZR statistical software (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a modified version of the R commander designed to add specific statistical functions commonly used in bio - statistics (Kanda 2013).”
MethodErdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,700
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
Self-citationHashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922 · cited 1×
“Therefore, several guidelines recommend the use of anti-EGFR mAb as a first-line treatment for patients with left-sided RAS/BRAF WT mCRC (Hashiguchi et al. 2020).”
BackgroundRECIST 1.1—Update and clarification: From the RECIST committee
Schwartz, L. H., Litière, S., de Vries, E., Ford, R., Gwyther, S., Mandrekar, S., Shankar, L., Bogaerts, J., Chen, A., Dancey, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.081 · Cited by 1,906 · cited 1×
“1) (Schwartz et al. 2016).”
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“…status is typically assessed prior to the initiation of systemic chemotherapy, most patients develop acquired resistance even after an initial response to chemotherapy containing anti-EGFR mAb (Misale et al. 2012; Siravegna et al. 2016), indicating changes in cancer clones and/or genetic status.”
BackgroundCervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796 · cited 1×
“…mCRC, right-sided tumors might benefit less in terms of progression-free survival (PFS) and overall survival (OS) from treatment with anti-EGFR mAb compared with left-sided tumors, but anti-EGFR mAb may be effective in terms of tumor shrinkage regardless of tumor sidedness (Cervantes et al. 2023).”
BackgroundClonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082 · cited 1×
“Mutant RAS clones have been reported to emerge in the blood during anti-EGFR mAb treatment and to decline treatment discontinuation, suggesting that the clonal evolution relates to clinical progression (Morelli et al. 2015; Siravegna et al. 2015; Siena et al. 2018 ; Parseghian et al. 2019).”
BackgroundLiquid biopsy: current technology and clinical applications
Nikanjam, M., Kato, S., & Kurzrock, R. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01351-y · Cited by 931 · cited 1×
“We used the OncoBEAM™ RAS CRC Kit, which detects 34 mutations in KRAS / NRAS codons 12, 13, 59, 61, 117, and 146 at an allele frequency of 0.01% (Nikanjam et al. 2022).”
MethodInfluentialTrifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer
Prager, G. W., Taieb, J., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Cruz, F. M., Wyrwicz, L., Stroyakovskiy, D., Pápai, Z., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214963 · Cited by 467
Cited by
Palieri, R., Luca, M. D., Balestra, F., Panzetta, G., Lotesoriere, C., Rizzi, F. R., Ricci, A. D., Mastrogiacomo, R., Curri, M. L., Laghi, L., et al. (2025) · Oncology Reviews · doi:10.3389/or.2025.1702932 · Cited by 17
Huang, A. H., Lee, G. Y., Lu, C. A., Şahin, İ. H., King, G. T., Safyan, R. A., Cohen, S. A., Zhen, D. B., Shankaran, V., Harris, W. P., et al. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00646 · Cited by 4
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“Studies such as CRICKET and CAVE have demonstrated that patients with elimination of resistant RAS and EGFR mutant clones can regain sensitivity to cetuximab-based therapy, reinforcing the need to integrate molecular monitoring into clinical decision-making [68,69].”
Toyokawa, E., Ooki, A., Shinozaki, E., Yoshikawa, K., Suzuki, K., Shiozawa, M., Maeda, S., Yamaguchi, K., & Osumi, H. (2026) · Biomolecules · doi:10.3390/biom16040543 · Cited by 1
“Comparable results have also been reported in real-world retrospective cohorts [92].”
Self-citationSagawa, T., & Fujikawa, K. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01510-1
“Similarly, liver-dominant disease, high tumor burden, rapid progression, and poor clinical tempo may reduce confidence in a negative plasma result because they may reflect aggressive biology or high likeli - hood of occult resistance [3, 6].”
InfluentialRarasati, A. R., Ramadhanti, J., Ma’ruf, I. F., Rohmawaty, E., Bashari, M. H., & Wiraswati, H. L. (2026) · Cancer Management and Research · doi:10.2147/cmar.s612902
Kagawa, Y., Kotani, D., Taniguchi, H., Hashimoto, T., Bando, H., Takahashi, N., Hamaguchi, T., Kanazawa, A., Kato, T., Ando, K., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01898-8
Self-citationRevisiting Cell Death in Colorectal Cancer: The Rise of Ferroptosis as a Therapeutic Opportunity
ALTamimi, A. O., Elemam, N. M., Kalady, M. F., & Talaat, I. M. (2026) · Journal of Cellular Physiology · doi:10.1002/jcp.70237
“H/dMMR tumors, but most mCRC are microsatellite stable and respond poorly to checkpoint blockade alone (Fukuda et al. 2024; San‐ Román‐Gil et al. 2024; Taniguchi et al. 2025; Wang et al. 2024; Xiao et al. 2023).”
Metadata
- Authors
- Fukuda, K., Osumi, H., Yoshinami, Y., Ooki, A., Takashima, A., Wakatsuki, T., Hirano, H., Nakayama, I., Ouchi, K., Sawada, R., Fukuoka, S., Ogura, M., Takahari, D., Chin, K., Shoji, H., Okita, N., Kato, K., Ishizuka, N., Boku, N., Yamaguchi, K., & Shinozaki, E.
- Affiliations
- The Cancer Institute Hospital (JP)
- National Cancer Center Hospital (JP)
- Tohoku University Hospital (JP)
- Jikei University School of Medicine (JP)
- Kyoto University (JP)
- IMSUT Hospital (JP)
- Corresponding author
- Shinozaki, Eiji
- ORCID
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2024-07-27
- Volume
- 150
- Issue
- 7
- Pages
- 369-369
- ISSN
- 0084-5353 (ISSN-L)
- 1432-1335
- PMC
- PMC11283376
- OpenAlex
- W4401052054
- Cited by
- 5
- References
- 39
- Citations by year
- 2026: 3 · 2025: 2
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Cancer Research and Clinical Oncology (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, anti-EGFR monoclonal antibody, circulating tumor DNA, RAS mutations, BRAF wild-type, progression-free survival, liver metastasis, first-line chemotherapy response, predictive biomarkers
- MeSH terms
- Circulating Tumor DNA, Antineoplastic Agents, Immunological, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mutation, Retrospective Studies, Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.